FLUORETH-LAD

FLUORETH-LAD
Clinical data
Other names	TRALA-15; FE-LAD; 6-(2-Fluoroethyl)-6-nor-LSD; 6-(2-Fluoroethyl)-LAD; N,N-Diethyl-6-(2-fluoroethyl)-9,10-didehydroergoline-8β-carboxamide
Drug class	Serotonin receptor modulator
Identifiers
	IUPAC name (6aR,9R)-N,N-diethyl-7-(2-fluoroethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	2757566-18-8 ;
PubChem CID	168105608;
Chemical and physical data
Formula	C21H26FN3O
Molar mass	355.457 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCF;
	InChI InChI=1S/C21H26FN3O/c1-3-24(4-2)21(26)15-10-17-16-6-5-7-18-20(16)14(12-23-18)11-19(17)25(13-15)9-8-22/h5-7,10,12,15,19,23H,3-4,8-9,11,13H2,1-2H3/t15-,19-/m1/s1; Key:UYFDKYZWVLEHQH-DNVCBOLYSA-N;

FLUORETH-LAD (TRALA-15), or FE-LAD, also known as 6-(2-fluoroethyl)-LAD or 6-(2-fluoroethyl)-6-nor-LSD, is a lysergamide derivative. It was first proposed by Alexander and Ann Shulgin in their book TiHKAL, but was never synthesised by Shulgin. Synthesis and activity data for the compound were first reported in a 2022 patent by Matthias Grill, in which pharmacological testing showed it to have similar affinity to LSD at some targets such as the 5-HT_1A and 5-HT_2A serotonin receptors, but much lower affinity at other targets such as 5-HT_2C and at dopamine receptors, giving it comparatively greater selectivity compared to LSD. Currently new lysergamide derivates are in the development phase at MiHKAL GmbH in Switzerland.